Table 5.
Comparison of baseline metabolic/cellular parameters between patients who improved liver fibrosis and those who did not.
| Baseline Parameter | F3/4 (before DAAs Treatment) to F1/2 (after DAAs Treatment) | F3/4 (before DAAS Treatment) to F3/4 (after DAAs Treatment) | p-Value * | ||
|---|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | ||
| ALP (UI/L) | 83.04 | [71.10–94.98] | 101.30 | [81.13–121.47] | 0.179 |
| AST (UI/L) | 79.96 | [57.10–102.81] | 84.85 | [69.36–100.34] | 0.234 |
| ALT (UI/L) | 101.79 | [70.65–132.94] | 99.56 | [75.48–123.63] | 0.692 |
| γGT (UI/L) | 134.63 | [78.44–190.81] | 126.37 | [82.01–170.73] | 0.727 |
| Hp (mg/dL) | 100.05 | [76.57–123.52] | 78.24 | [59.70–96.78] | 0.115 |
| TC (mmol/L) | 4.25 | [3.84–4.65] | 4.38 | [4.00–4.76] | 0.771 |
| HDL (mmol/L) | 1.71 | [1.40–2.02] | 1.44 | [1.17–1.71] | 0.039 |
| LDL (mmol/L) | 2.09 | [1.78–2.39] | 2.34 | [2.05–2.63] | 0.179 |
| TG (mmol/L) | 1.26 | [1.06–1.46] | 1.33 | [1.11–1.55] | 0.880 |
| Fe (μg/dL) | 128 | [107.22–148−78] | 132.19 | [113.29–151.08] | 0.514 |
| TS (%) | 36.96 | [29.90–44.02] | 40.52 | [33.17–47.86] | 0.325 |
| TIBC (μg/dL) | 329.65 | [307.47–351.83] | 343.15 | [311.54–374.76] | 0.381 |
| FT (ng/mL) | 277.26 | [167.53–386.99] | 331.78 | [230.38–433.18] | 0.465 |
| Platelets count (U/µL) | 2.11 × 105 | [1.78 × 105–2.44 × 105] | 1.49 × 105 | [1.16 × 105–1.82 × 105] | 0.003 |
| Glycaemia (mg/dL) | 95.87 | [82.90–108.84] | 113.04 | [93.33–132.75] | 0.070 |
| Insulin (mcU/mL) | 11.05 | [8.53–13.56] | 19.00 | [14.20–23.80] | 0.004 |
| HOMA-IR | 2.76 | [1.74–3.79] | 5.82 | [3.98–7.66] | 0.006 |
* Mann-Whitney Test; 95% CI—95% confidence interval for mean.